Mallinckrodt PLC Company Profile (NYSE:MNK)

About Mallinckrodt PLC (NYSE:MNK)

Mallinckrodt PLC logoMallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:MNK
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.61522 billion
  • Outstanding Shares: 99,347,000
Average Prices:
  • 50 Day Moving Avg: $42.28
  • 200 Day Moving Avg: $45.03
  • 52 Week Range: $35.04 - $85.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 4.43
  • P/E Growth: 0.86
Sales & Book Value:
  • Annual Revenue: $3.27 billion
  • Price / Sales: 1.10
  • Book Value: $52.46 per share
  • Price / Book: 0.69
  • EBIDTA: $666.6 million
  • Net Margins: 12.64%
  • Return on Equity: 15.28%
  • Return on Assets: 5.20%
  • Debt-to-Equity Ratio: 1.05%
  • Current Ratio: 1.06%
  • Quick Ratio: 0.81%
  • Average Volume: 2.64 million shs.
  • Beta: 1.52
  • Short Ratio: 7.62

Frequently Asked Questions for Mallinckrodt PLC (NYSE:MNK)

What is Mallinckrodt PLC's stock symbol?

Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt PLC's stock buyback program work?

Mallinckrodt PLC announced that its Board of Directors has initiated a share repurchase plan on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 18.5% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its stock is undervalued.

How were Mallinckrodt PLC's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) announced its earnings results on Tuesday, August, 8th. The company reported $1.85 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.73 by $0.12. The company earned $824.50 million during the quarter, compared to analysts' expectations of $829.56 million. Mallinckrodt PLC had a return on equity of 15.28% and a net margin of 12.64%. The business's revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.03 earnings per share. View Mallinckrodt PLC's Earnings History.

When will Mallinckrodt PLC make its next earnings announcement?

Mallinckrodt PLC is scheduled to release their next quarterly earnings announcement on Tuesday, December, 5th 2017. View Earnings Estimates for Mallinckrodt PLC.

What guidance has Mallinckrodt PLC issued on next quarter's earnings?

Mallinckrodt PLC issued an update on its FY17 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of $7.40-8.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.53.

Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?

16 brokers have issued 1 year price objectives for Mallinckrodt PLC's stock. Their forecasts range from $52.00 to $98.00. On average, they anticipate Mallinckrodt PLC's stock price to reach $73.03 in the next year. View Analyst Ratings for Mallinckrodt PLC.

What are analysts saying about Mallinckrodt PLC stock?

Here are some recent quotes from research analysts about Mallinckrodt PLC stock:

  • 1. According to Zacks Investment Research, "Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business due to lingering challenging conditions for quite some time. The company also sold its Intrathecal Therapy business to focus on its key areas. Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments. The company is working on expanding Acthar's label further. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Weakness in shares persist as shares have underperformed the Medical-Generic Drugs industry so far in 2017." (7/27/2017)
  • 2. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
  • 3. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)

Who are some of Mallinckrodt PLC's key competitors?

Who are Mallinckrodt PLC's key executives?

Mallinckrodt PLC's management team includes the folowing people:

  • Melvin D. Booth Ph.D., CPA, Independent Chairman of the Board
  • Mark C. Trudeau, President, Chief Executive Officer, Director
  • Matthew K. Harbaugh, Chief Financial Officer, Executive Vice President
  • Ian J. Watkins, Chief Human Resource Officer
  • Ronald K. Lloyd, Executive Vice President and President - Hospital Therapies
  • Gary M. Phillips M.D., Executive Vice President and Chief Strategy Officer
  • Steven Romano, Executive Vice President and Chief Scientific Officer
  • Frank Scholz, Executive Vice President of Global Operations and President - Specialty Generics
  • Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases
  • Raymond J. Furey, Chief Compliance Officer

Who owns Mallinckrodt PLC stock?

Mallinckrodt PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.04%), BlackRock Inc. (8.02%), State Street Corp (5.09%), Alliancebernstein L.P. (3.37%), HealthCor Management L.P. (2.42%) and Dimensional Fund Advisors LP (2.18%). Company insiders that own Mallinckrodt PLC stock include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Institutional Ownership Trends for Mallinckrodt PLC.

Who sold Mallinckrodt PLC stock? Who is selling Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., BlackRock Inc., Acadian Asset Management LLC, Royal Bank of Canada, Vanguard Group Inc., GAM Holding AG, Northern Trust Corp and State Street Corp. View Insider Buying and Selling for Mallinckrodt PLC.

Who bought Mallinckrodt PLC stock? Who is buying Mallinckrodt PLC stock?

Mallinckrodt PLC's stock was purchased by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Janus Henderson Group PLC, Ameriprise Financial Inc., AJO LP, Dimensional Fund Advisors LP, FMR LLC, Alliancebernstein L.P. and LSV Asset Management. Company insiders that have bought Mallinckrodt PLC stock in the last two years include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Insider Buying and Selling for Mallinckrodt PLC.

How do I buy Mallinckrodt PLC stock?

Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt PLC's stock price today?

One share of Mallinckrodt PLC stock can currently be purchased for approximately $36.13.

MarketBeat Community Rating for Mallinckrodt PLC (NYSE MNK)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  514 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  777
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $73.03 (102.13% upside)

Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/9/2017MizuhoReiterated RatingBuy$73.00 -> $70.00MediumView Rating Details
8/9/2017BMO Capital MarketsReiterated RatingOutperform$69.00 -> $65.00LowView Rating Details
8/9/2017Raymond James Financial, Inc.Lower Price TargetOutperform$65.00 -> $58.00LowView Rating Details
8/9/2017Deutsche Bank AGSet Price TargetBuy$68.00 -> $56.00LowView Rating Details
8/8/2017Canaccord GenuitySet Price TargetBuy$87.00HighView Rating Details
8/8/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$70.00HighView Rating Details
8/7/2017Piper Jaffray CompaniesSet Price TargetBuy$85.00MediumView Rating Details
8/3/2017Jefferies Group LLCReiterated RatingBuy$70.00MediumView Rating Details
6/21/2017Wells Fargo & CompanyReiterated RatingOutperform$83.50HighView Rating Details
6/16/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$52.00LowView Rating Details
5/31/2017Morgan StanleySet Price TargetBuy$65.00LowView Rating Details
4/1/2017GuggenheimSet Price TargetBuy$98.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
1/25/2017J P Morgan Chase & CoSet Price TargetHold$78.00N/AView Rating Details
8/26/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$83.00N/AView Rating Details
8/25/2016Barclays PLCReiterated RatingOverweight$88.00N/AView Rating Details
8/12/2016Stifel NicolausInitiated CoverageBuy$95.00N/AView Rating Details
3/16/2016Northland SecuritiesReiterated RatingBuy$95.00N/AView Rating Details
2/2/2016NomuraReiterated RatingNeutral$100.00N/AView Rating Details
10/7/2015Bank of America CorporationLower Price TargetBuy$135.00 -> $131.00N/AView Rating Details
(Data available from 8/22/2015 forward)


Earnings History for Mallinckrodt PLC (NYSE:MNK)
Earnings by Quarter for Mallinckrodt PLC (NYSE:MNK)
Earnings History by Quarter for Mallinckrodt PLC (NYSE MNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017$1.73$1.85$829.56 million$824.50 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.63$1.68$781.23 million$810.90 millionViewListenView Earnings Details
2/7/2017Q117$1.82$1.91$827.12 million$829.90 millionViewListenView Earnings Details
11/29/2016Q416$1.98$2.04$880.10 million$887.20 millionViewListenView Earnings Details
8/2/2016Q316$2.01$2.20$920.35 million$970.60 millionViewListenView Earnings Details
5/3/2016Q216$1.72$2.01$878.70 million$918.00 millionViewListenView Earnings Details
2/2/2016Q116$1.78$2.09$888.33 million$915.00 millionViewListenView Earnings Details
11/23/2015Q415$1.77$1.84$869.41 million$882.40 millionViewListenView Earnings Details
8/4/2015Q315$1.82$2.05$983.81 million$965.10 millionViewListenView Earnings Details
5/5/2015Q215$1.48$1.72$860.89 million$909.90 millionViewListenView Earnings Details
2/3/2015Q115$1.57$1.84$880.12 million$866.00 millionViewListenView Earnings Details
11/19/2014Q414$1.41$1.68$759.04 million$789.00 millionViewListenView Earnings Details
8/7/2014Q314$0.86$1.20$278.80 million$653.10 millionViewListenView Earnings Details
5/8/2014Q214$0.79$0.95$566.50 million$557.80 millionViewListenView Earnings Details
2/6/2014Q1$0.66$0.88$539.24 million$540.20 millionViewListenView Earnings Details
11/7/2013$0.85$1.02$572.57 million$552.20 millionViewListenView Earnings Details
8/9/2013Q3 2013$0.78$0.49$557.22 million$570.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)
2017 EPS Consensus Estimate: $7.55
2018 EPS Consensus Estimate: $8.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.54$1.84$1.71
Q2 20173$1.70$1.95$1.80
Q3 20173$1.88$1.89$1.89
Q4 20173$2.02$2.35$2.16
Q1 20183$1.82$2.06$1.93
Q2 20181$2.09$2.09$2.09
Q3 20181$2.03$2.03$2.03
Q4 20181$2.48$2.48$2.48
(Data provided by Zacks Investment Research)


Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Mallinckrodt PLC (NYSE:MNK)
Insider Ownership Percentage: 0.53%
Institutional Ownership Percentage: 94.65%
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Institutional Ownership by Quarter for Mallinckrodt PLC (NYSE:MNK)
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2017Steven J. RomanoVPBuy1,000$39.88$39,880.00View SEC Filing  
6/8/2017Hugh M. O'neillVPBuy1,000$40.24$40,240.00View SEC Filing  
6/5/2017Coleman N Lannum IIIVPBuy500$39.33$19,665.00View SEC Filing  
6/2/2017Coleman N Lannum IIIVPBuy1,350$42.89$57,901.50View SEC Filing  
5/12/2017Coleman N. Lannum IIIVPBuy1,968$46.20$90,921.60View SEC Filing  
3/10/2017Matthew K. HarbaughCFOBuy600$49.19$29,514.00View SEC Filing  
3/7/2017Michael-Bryant HicksGeneral CounselBuy290$50.35$14,601.50View SEC Filing  
2/23/2017Meredith B. FischerInsiderBuy2,000$54.34$108,680.00View SEC Filing  
2/14/2017Mark TrudeauInsiderBuy1,000$50.47$50,470.00View SEC Filing  
2/10/2017Steven J. RomanoVPBuy1,000$49.68$49,680.00View SEC Filing  
5/10/2016Hugh M O'neillVPBuy1,653$60.99$100,816.47View SEC Filing  
5/10/2016Matthew K HarbaughCFOBuy500$59.37$29,685.00View SEC Filing  
5/6/2016Mark TrudeauCEOBuy1,000$56.02$56,020.00View SEC Filing  
5/6/2016Steven J RomanoVPBuy900$56.00$50,400.00View SEC Filing  
3/4/2016Coleman N Lannum IIIVPBuy2,600$62.63$162,838.00View SEC Filing  
2/26/2016Meredith B FischerVPBuy1,400$69.80$97,720.00View SEC Filing  
2/12/2016Coleman N Lannum IIIVPBuy600$59.66$35,796.00View SEC Filing  
2/10/2016Coleman N Lannum IIIVPBuy1,300$62.58$81,354.00View SEC Filing  
2/9/2016Matthew K. HarbaughCFOBuy1,300$63.00$81,900.00View SEC Filing  
2/8/2016Coleman N. Lannum IIIVPBuy800$66.37$53,096.00View SEC Filing  
12/22/2015Coleman N Lannum IIISVPBuy500$72.50$36,250.00View SEC Filing  
12/11/2015Terrance L CarlsonGeneral CounselBuy1,000$69.10$69,100.00View SEC Filing  
12/2/2015Gary M. PhillipsVPBuy1,000$72.17$72,170.00View SEC Filing  
11/30/2015Mark TrudeauCEOBuy1,350$65.89$88,951.50View SEC Filing  
11/27/2015Coleman N Lannum IIISVPBuy1,200$66.86$80,232.00View SEC Filing  
11/27/2015Meredith B FischerVPBuy2,200$66.93$147,246.00View SEC Filing  
11/27/2015Terrance L CarlsonGeneral CounselBuy1,000$66.54$66,540.00View SEC Filing  
8/25/2015Hugh M O'neillSVPBuy1,197$83.52$99,973.44View SEC Filing  
8/25/2015Mark TrudeauCEOBuy1,000$83.08$83,080.00View SEC Filing  
8/21/2015Coleman N Lannum IIISVPBuy2,375$88.52$210,235.00View SEC Filing  
8/21/2015Mark TrudeauCEOBuy2,000$88.45$176,900.00View SEC Filing  
6/4/2015Coleman N Lannum IIIVPBuy1,300$126.41$164,333.00View SEC Filing  
6/2/2015Matthew K HarbaughCFOSell22,106$128.64$2,843,715.84View SEC Filing  
5/18/2015Mario D SaltarelliVPSell4,580$127.44$583,675.20View SEC Filing  
5/13/2015Don M BaileyDirectorSell51,417$122.45$6,296,011.65View SEC Filing  
5/11/2015Sandra L HattenVPSell2,024$122.29$247,514.96View SEC Filing  
4/13/2015Don M BaileyDirectorSell40,000$127.61$5,104,400.00View SEC Filing  
3/13/2015Don M BaileyDirectorSell40,000$123.40$4,936,000.00View SEC Filing  
2/13/2015Don M BaileyDirectorSell33,891$114.63$3,884,925.33View SEC Filing  
2/2/2015Mark TrudeauCEOSell11,925$105.94$1,263,334.50View SEC Filing  
1/9/2015Mark TrudeauCEOSell15,720$102.00$1,603,440.00View SEC Filing  
12/22/2014Peter G EdwardsVPSell1,265$99.69$126,107.85View SEC Filing  
12/18/2014Mark TrudeauCEOSell13,831$93.59$1,294,443.29View SEC Filing  
9/10/2014Raymond J FureyVPSell5,441$85.90$467,381.90View SEC Filing  
9/8/2014Don M BaileyDirectorSell221,177$85.23$18,850,915.71View SEC Filing  
9/5/2014Raymond J FureyVPSell15,000$85.47$1,282,050.00View SEC Filing  
9/5/2014Virgil D ThompsonDirectorSell25,000$83.76$2,094,000.00View SEC Filing  
9/2/2014Raymond J FureyVPSell10,303$81.61$840,827.83View SEC Filing  
8/29/2014Raymond J FureyVPSell4,840$80.90$391,556.00View SEC Filing  
8/19/2014Joseph A ZaccagninoDirectorBuy3,000$71.06$213,180.00View SEC Filing  
8/13/2014Paulson & Co IncMajor ShareholderBuy132,100$69.80$9,220,580.00View SEC Filing  
8/12/2014J Martin CarrollDirectorBuy2,000$69.24$138,480.00View SEC Filing  
8/12/2014Paulson & Co IncMajor ShareholderBuy467,900$68.78$32,182,162.00View SEC Filing  
8/11/2014Paulson & Co IncMajor ShareholderBuy207,900$69.70$14,490,630.00View SEC Filing  
8/7/2014Paulson & Co IncMajor ShareholderBuy700,200$70.15$49,119,030.00View SEC Filing  
8/1/2014Paulson & Co IncMajor ShareholderBuy275,000$69.60$19,140,000.00View SEC Filing  
6/11/2014Melvin D BoothDirectorBuy4,000$76.05$304,200.00View SEC Filing  
5/9/2014Paulson & Co Incmajor shareholderBuy786,207$73.63$57,888,421.41View SEC Filing  
2/3/2014Mark TrudeauCEOSell14,890$56.12$835,626.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mallinckrodt PLC (NYSE:MNK)
Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
DateHeadline logoMallinckrodt PLC (MNK) Downgraded by BidaskClub to Strong Sell - August 18 at 9:32 PM logoAnalyst: Mallinckrodt Stock Is Undervalued - Benzinga - August 17 at 8:37 PM logoMallinckrodt: FDA Chief Comments Are Another Negative - Seeking Alpha - August 17 at 3:34 PM logoAnalyst: Mallinckrodt Stock Is Undervalued - August 17 at 3:58 AM logoMallinckrodt Plc – Value Analysis (NYSE:MNK) : August 17, 2017 - August 17 at 3:58 AM logoMallinckrodt To Present At Morgan Stanley 15th Annual Global Healthcare Conference - August 16 at 6:14 AM logoMallinckrodt (MNK) Looks Strong on Acthar, Generics Weak - August 16 at 6:13 AM logoMallinckrodt PLC to Post FY2018 Earnings of $7.86 Per Share, Cantor Fitzgerald Forecasts (MNK) - August 14 at 8:36 AM logoMallinkcrodt Confidence Is Starting To Crack - Seeking Alpha - August 13 at 12:58 AM logoMallinckrodt's Demise Will Not Be Orderly - Seeking Alpha - August 13 at 12:58 AM logoMallinckrodt PLC (MNK) to Post Q4 2017 Earnings of $2.10 Per Share, Oppenheimer Holdings Forecasts - August 11 at 1:04 PM logoSee what the IHS Markit Score report has to say about Mallinckrodt Plc. - August 11 at 6:34 AM logoOppenheimer Holdings Comments on Mallinckrodt PLC's Q3 2017 Earnings (NYSE:MNK) - August 10 at 11:56 AM logoMallinckrodt plc (MNK) PT Lowered to $65 at BMO Capital on 2Q Report; 'Reaffirmed 2017 EPS Guidance' - August 10 at 5:40 AM logoMallinckrodt Was the S&P 500’s Biggest Loser on August 8 - August 10 at 5:40 AM logoMallinckrodt PLC (NYSE:MNK) Stock Rating Reaffirmed by Mizuho - August 9 at 5:56 PM logoBMO Capital Markets Lowers Mallinckrodt PLC (MNK) Price Target to $65.00 - August 9 at 2:08 PM logoMallinckrodt PLC (NYSE:MNK) Price Target Cut to $58.00 - August 9 at 2:08 PM logoMallinckrodt Becomes Oversold (MNK) - August 9 at 12:35 AM logoInvestor Network: Mallinckrodt Plc to Host Earnings Call - August 9 at 12:35 AM logoMallinckrodt plc Reports Earnings Results for Second Quarter of Fiscal 2017 - August 9 at 12:35 AM logoMallinckrodt (MNK) Tops Q2 Earnings, Misses on Sales - August 9 at 12:35 AM logoIt's been a hideous morning for Wall Street's most hated pharma stock - August 9 at 12:35 AM logoEdited Transcript of MNK earnings conference call or presentation 8-Aug-17 12:30pm GMT - August 9 at 12:35 AM logoMallinckrodt beats 2Q profit forecasts - August 9 at 12:35 AM logoOppenheimer Holdings, Inc. Analysts Give Mallinckrodt PLC (NYSE:MNK) a $70.00 Price Target - August 8 at 6:26 PM logoMallinckrodt PLC (NYSE:MNK) Releases Earnings Results, Beats Expectations By $0.12 EPS - August 8 at 1:10 PM logoMallinckrodt PLC (NYSE:MNK) Releases FY17 Earnings Guidance - August 8 at 9:58 AM logoMallinckrodt To Present At Wells Fargo Securities 2017 Healthcare Conference - August 7 at 8:03 PM logoMultnomah County seeks $250M from Purdue, other opioid manufacturers - August 7 at 8:03 PM logoMallinckrodt PLC (MNK) Expected to Post Quarterly Sales of $827.35 Million - August 7 at 7:54 AM logoWhy Mallinckrodt (MNK) Might Surprise This Earnings Season - Nasdaq - August 6 at 12:38 AM logoMallinckrodt to buy InfaCare Pharmaceutical for up to $425M ... - Seeking Alpha - August 5 at 7:37 PM logoThe Clock Is Ticking On Mallinckrodt - Seeking Alpha - August 5 at 7:37 PM logoMallinckrodt (MNK) to Acquire InfaCare Pharmaceutical and its Stannsoporfin - August 5 at 3:54 AM logoMallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe Jaundice - August 5 at 3:54 AM logoWhy Mallinckrodt (MNK) Might Surprise This Earnings Season - August 5 at 3:54 AM logoMallinckrodt Plc breached its 50 day moving average in a Bearish Manner : MNK-US : August 3, 2017 - August 4 at 2:09 AM logoMallinckrodt Enrolls First Patient In Phase 4 Registry Of INOMAX® (Nitric Oxide) Gas For Inhalation For Pulmonary Hypertension In Neonates - August 2 at 5:55 AM logoCan Mallinckrodt (MNK) Deliver a Beat this Earnings Season? - August 2 at 5:55 AM logoMallinckrodt PLC (NYSE:MNK) Scheduled to Post Quarterly Earnings on Tuesday - August 1 at 9:58 AM logoMallinckrodt (MNK) Says Summary Review of Clinical and Economic Data on HP Acthar Gel Published in Advances in ... - - July 31 at 8:25 PM logoSummary Review of Clinical and Economic Data on H.P. Acthar® Gel (Repository Corticotropin Injection) Published in Advances in Therapy - July 31 at 8:24 PM logoMallinckrodt PLC (MNK) Earns "Buy" Rating from BMO Capital Markets - July 29 at 11:52 AM logoMallinckrodt PLC (NYSE:MNK) Receives Consensus Recommendation of "Buy" from Analysts - July 29 at 7:50 AM logoMcCaskill expands opioid probe to include Mallinckrodt - July 28 at 4:25 PM logoStull, Stull & Brody Announces Class Action Lawsuit on Behalf of Employee Benefit Plan Purchasers of Mallinckrodt ... - GlobeNewswire (press release) - July 27 at 4:24 AM logoStull, Stull & Brody Announces Class Action Lawsuit on Behalf of Employee Benefit Plan Purchasers of Mallinckrodt plc Stock - July 27 at 4:24 AM logoETFs with exposure to Mallinckrodt Plc : July 24, 2017 - July 24 at 7:09 PM logoMallinckrodt triples its spending on lobbying - July 22 at 6:31 AM



Mallinckrodt PLC (MNK) Chart for Tuesday, August, 22, 2017

This page was last updated on 8/22/2017 by Staff